Mirtazapine was significantly more effective than a serotonin-noradrenaline reuptake inhibitor ( venlafaxine only , two trials , n = 415 ) at two weeks ( OR 2.29 , 95 % CI 1.45 to 3.59 ) and at the end of acute-phase treatment ( OR 1.53 , 95 % CI 1.03 to 2.25).In terms of dropouts , there was no robust evidence to detect a difference between mirtazapine and other antidepressants .
Mirtazapine was more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction .
AUTHORS ' CONCLUSIONS Some statistically significant and possibly clinical ly meaningful differences between mirtazapine and other antidepressive agents were found for the acute-phase treatment of major depression .
Mirtazapine is likely to have a faster onset of action than SSRIs during the acute-phase treatment .
Dropouts occur similarly in participants treated with mirtazapine and those treated with other antidepressants , although the adverse event profile of mirtazapine is unique
BACKGROUND Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice .
OBJECTIVES The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults .
A National Survey of Cardiovascular Physicians' Beliefs and Clinical Care Practices When Diagnosing and Treating Depression in Patients With Cardiovascular Disease
A national survey was administered to determine 1 ) cardiovascular physicians ' beliefs about the association between depression and cardiovascular disease ( CVD ) , 2 ) the methods used to diagnose depression , 3 ) referral patterns for treatment of depression , and 4 ) frequency of use and preferred choice of antidepressant . A national survey of 50 % of r and omly selected U.S. cardiovascular physicians belonging to the American College of Cardiology was conducted ; 796 of 8854 physicians who received the question naires responded . Cardiovascular physicians were aware of indirect associations between depression and coronary artery disease ( CAD ) . However , 49.9 % were unaware of depression as an independent cardiac risk factor ; 71.2 % asked less than half their patients with CAD about depression ; 79 % used no st and ard screening method to diagnose depression . Among cardiovascular physicians , 84.8 % reported that between 1 % and 50 % of their patients have depression , and 49.2 % indicated that they treat the symptoms of depression in their patients with CAD . Cardiovascular physicians often refer depressed patients with CAD to mental health professionals and recommend exercise , relaxation training , stress management , psychotherapy , and diaries for their patients . Among cardiovascular physicians , 55.5 % treat depression/CAD with antidepressant medication : sertraline ( 28 % ) , paroxetine ( 16.1 % ) , fluoxetine ( 10.8 % ) , escitalopram ( 8.7 % ) , citalopram ( 7.9 % ) , bupropion ( 4.4 % ) , tricyclic antidepressants ( 3.8 % ) , and venlafaxine 2.9 %
Mirtazapine was significantly more effective than a serotonin-noradrenaline reuptake inhibitor ( venlafaxine only , two trials , n = 415 ) at two weeks ( OR 2.29 , 95 % CI 1.45 to 3.59 ) and at the end of acute-phase treatment ( OR 1.53 , 95 % CI 1.03 to 2.25).In terms of dropouts , there was no robust evidence to detect a difference between mirtazapine and other antidepressants .
Mirtazapine was more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction .
AUTHORS ' CONCLUSIONS Some statistically significant and possibly clinical ly meaningful differences between mirtazapine and other antidepressive agents were found for the acute-phase treatment of major depression .
Mirtazapine is likely to have a faster onset of action than SSRIs during the acute-phase treatment .
Dropouts occur similarly in participants treated with mirtazapine and those treated with other antidepressants , although the adverse event profile of mirtazapine is unique
BACKGROUND Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice .
OBJECTIVES The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults .